Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DeLLphi-307 tarlatamab in previously treated advanced small cell lung cancer in China
ChiCTR2500103532Phase 2Completed
- Sponsor
- Tongji Hospital
- Start
- May 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tarlatamab in small cell lung cancer (SCLC), sponsored by Tongji Hospital. Primary endpoint: Objective response rate. Started May 2025; status: completed.
02
Drugs
tarlatamab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2500103532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500103532.